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Proton beams are promising means for treating tumors. Such charged particles stop at 
a defined depth, where the ionization density is maximum. As the dose deposit beyond 
this distal edge is very low, proton therapy minimizes the damage to normal tissue 
compared to photon therapy. Nevertheless, inherent range uncertainties cast doubts 
on the irradiation of tumors close to organs at risk and lead to the application of con-
servative safety margins. This constrains significantly the potential benefits of protons 
over photons. In this context, several research groups are developing experimental tools 
for range verification based on the detection of prompt gammas, a nuclear by-product 
of the proton irradiation. At OncoRay and Helmholtz-Zentrum Dresden-Rossendorf, 
detector components have been characterized in realistic radiation environments as a 
step toward a clinical Compton camera. On the one hand, corresponding experimental 
methods and results obtained during the ENTERVISION training network are reviewed. 
On the other hand, a novel method based on timing spectroscopy has been proposed 
as an alternative to collimated imaging systems. The first tests of the timing method at 
a clinical proton accelerator are summarized, its applicability in a clinical environment for 
challenging the current safety margins is assessed, and the factors limiting its precision 
are discussed.
Keywords: proton therapy, range verification, in vivo dosimetry, Compton imaging, block detector, scintillation, 
prompt gamma ray timing
1. iNTRODUCTiON
In the first decades of the 20th century, during the rise of particle accelerators, physicists studied 
the interaction of fast charged particles with matter. The energy loss of heavy ions (as opposed to 
light electrons) within a target medium was described by Bethe’s stopping power formula (1). The 
ionization, namely, the Coulomb collisions where the accelerated ions strip out electrons of the atoms 
of the target, is the predominant loss mechanism for non-relativistic ion beams (2).
The engineering race toward high-energy accelerators endowed heavy charged particles a pen-
etration depth in tissue comparable to the body dimensions. This opened up the possibility of using 
protons for medical applications, as neutrons, electrons, gamma, or X-rays had been applied before 
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in the field of radiotherapy, which emerged after Röntgen’s X-ray 
discovery in 1895 (3).
In 1946, Wilson predicted the physical, in particular dosimet-
ric, properties of a proton beam (4) for a therapeutic scenario 
and founded the field of proton therapy. The straight beam 
trajectory, the finite particle range, as well as the increase of the 
ionization density close to the stopping point, aroused the interest 
of the medical community. In the context of cancer treatment, 
this ionizing radiation was expected to damage the cells of the 
target tumor and eventually cause their death, while sparing most 
efficiently surrounding normal tissue.
The first experimental treatments were performed dur-
ing the 1950s at Berkeley Radiation Laboratory, USA, and in 
Uppsala, Sweden (2, 5). However, it was not until 1990 that the 
first hospital-based proton facility in Loma Linda University 
(USA) was created. Since then, the number of therapy centers 
has increased steadily, and carbon or other ions have been also 
introduced. Nowadays, more than 15,000 patients are treated per 
year in around 50 facilities worldwide (5).
Several distinguishing features of accelerated protons are listed 
below:
•	 The particle range: the protons stop at a defined penetration 
depth, which depends on their initial velocity.
•	 The Bragg peak: the ionization cross section increases for low 
proton velocities, so that the dose deposition density is maxi-
mum close to the particle range (2). Conversely, the dose at the 
entrance point is minimum.
•	 The distal penumbra: beyond the particle range, the dose depo-
sition falls steeply to zero.
•	 The lateral penumbra: the beam trajectory is straight and the 
spread in the transversal dimension due to multiple Coulomb 
scattering is small but increases steadily with depth [(6), p. 15].
•	 Tissue composition: the dose deposition curve and proton 
range are strongly dependent on the stopping power of the 
traversed tissue (on its density and composition).
•	 Secondary products: neutrons, annihilation photons, and 
prompt gammas are produced throughout the proton track. 
These secondary by-products release a small dose compared to 
the incident protons (2), and they can exit the patient. Neutron 
emission is focused in forward direction (7).
In theory, proton therapy has several advantages over conven-
tional photon therapy:
•	 The distal edge: the steep dose gradient at the distal edge is 
promising for sparing critical organs close to the irradiated 
tumor. In contrast, the slowly falling depth dose curve of 
photons impedes that strategy.
•	 The integral dose: thanks to the Bragg peak, the dose can be 
focused on the tumor volume, and the damage on normal tissue 
before and beyond is minimized. For photons, the dose in healthy 
tissue can only be distributed on a larger volume by irradiating 
from several directions, but its integral is higher than for protons.
The main drawbacks compared to photons are:
•	 The capital expenditure on the facility construction and the 
higher clinical operating costs (8, 9).
•	 The lack of large clinical trials and evidence about the superi-
ority of proton beam therapy for the majority of tumor entities 
(10). Whether or not the lower integral dose translates to 
better clinical outcome (11), e.g., less normal-tissue toxicity, 
is yet to be proven.
•	 Range uncertainties (12) of the proton beam due to intrinsic 
factors, such as patient or organ motion, as well as restricted 
knowledge about the tissue composition, are prone to yield 
severe differences with respect to the planned dose, specially 
at the distal edge, whereas photon plans are much less sensitive 
in this regard (13). To circumvent the risk, safety margins are 
applied and robust treatment plans are designed, at the price 
of an increase of the dose in the normal tissue compared to the 
dose-optimum (but more risky) plan.
These disadvantages question the cost-effectiveness of ion 
beam therapy and fuel the controversy about their clinical 
superiority [(14), chapters 2.11–2.13] over photon therapy. 
There is an urgent need for techniques that tackle one of 
the major weaknesses of proton therapy: the intrinsic range 
uncertainties, which limit the ultimate precision with which 
ion beams can be safely delivered. The most common sources 
of range errors are:
•	 Stopping power ambiguity due to degeneracy of Hounsfield 
values depending on tissue composition (15).
•	 Patient alignment errors.
•	 Anatomy changes between or during treatment fractions, 
as cavity filling, change of weight, tissue swelling, or tumor 
shrinkage.
•	 Organ motion in the thoracic and abdominal region.
•	 Biological factors (16).
The proton range is strongly dependent on the composition of 
the traversed tissue. Photons are less dependent on these factors, 
and the absence of a sharp edge constrains the maximum dose 
deviations due to target shifts or path composition variations. 
The absence of tools in clinical routine for measuring in  vivo 
and in real time, the actual distal fall-off edge, together with the 
high sensitivity of the proton range to tissue composition, force 
medical physicists to add safety margins and apply field patch-
ing techniques in order to obtain a robust treatment plan (17). 
Notwithstanding the theoretically superior dose profile of ions, 
broad safety margins (Figure 1) waste substantially the outstand-
ing traits of ion over photon beam therapy.
It should be emphasized that most cancers are treated suc-
cessfully with surgery, electron or photon therapy, chemotherapy, 
brachytherapy, whereas proton therapy covers just a residual 
percentage (18). Still, the improvement in the accelerator tech-
nology, delivery systems, and the trend toward personalized 
medicine make proton beams an attractive alternative for certain 
patient ages and types of tumors. It is estimated that ~10% of 
cancer patients, especially children, would benefit from proton 
therapy (reduction of late side effects) compared to conventional 
techniques (18). Hence, proton therapy is still in the headlines, 
the number of facilities is increasing from year to year, and ques-
tions concerning the improvement of the technique and quality 
assurance are of great interest.
FiGURe 1 | Safety margins applied at different clinical proton therapy 
facilities: (3.5% + 3-mm) at Loma Linda University Medical Center 
(LLUMC) (3.5% + 2-mm) at Universitäts Protonen Therapie Dresden 
(UPTD) (3.5% + 1-mm) at Massachusetts General Hospital (MGH) and 
(2.5% + 1.5-mm) at University of Florida Health Proton Therapy 
institute (UFH). Range bonus refers to the margin added to the prescribed 
range to ensure full tumor coverage even in the case of an undershoot. 
These centers may apply bigger margins in specific treatment scenarios (62).
FiGURe 2 | Schematic of a typical prompt gamma ray production 
process 12C(p,p′)12C*. Left: nuclear collision of a proton (p) with a 12C 
nucleus of the target. Center: the proton is scattered (p′) and the nucleus is 
left in an excited state 12C*. Right: the relaxation to the ground state 12C is 
accompanied by a 4.4-MeV prompt gamma emission γp.
FiGURe 3 | Mean free path λ of photons of energy eγ in different 
representative materials: water (body), Csi (detector), and Pb 
(collimator). λ is calculated as the inverse of the total attenuation factor μ 
that is extracted from (63). Explicit points at typical energies are drawn: 
140-keV for 99Tc (nuclear medicine), 511-keV for PET, and 4-MeV for PGI.
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In this context, several groups across the world aim at an 
experimental device that measures the particle range and even the 
dose profile, preferably in real time (13). Numerous techniques 
have been proposed in the last two decades and are reviewed in 
Ref. (13, 19, 20). This paper fits into this context and summarizes 
two different methods for monitoring the dose delivery of proton 
beams in real time based on Prompt Gamma Imaging (PGI).
Prompt gamma rays, a by-product emitted in nuclear reactions 
along the proton track, cf. Figure 2, cover a broad energy spec-
trum with several prominent characteristic lines, cf. Ref. (21). The 
high gamma ray energy ensures that they can be detected outside 
the patient without severe attenuation. The spatial emission 
distribution correlates to the dose deposition map of the incident 
protons (21, 22) and provides an indirect measurement of the 
particle range. Such correlation is dependent on prompt gamma 
ray energy and tissue composition (23–26) and stems from the 
maximum of the nuclear cross section at low (~10-MeV) proton 
energies (27).
These gamma rays are prompt, i.e., they are emitted almost 
instantaneously after the collision, which is interesting for real-
time range verification. The gamma ray production over 1-MeV 
is considerable, around 0.16 per proton (on average) at 160-MeV 
beam energy (28). The gamma ray emission rate depends on the 
beam current, duty cycle, and micro-time structure of the consid-
ered accelerator. Taking as an example the Cyclone® 230 (C230) 
isochronous cyclotron of IBA (Louvain-la-Neuve, Belgium) and 
a realistic treatment plan with pencil beam scanning, the peak 
beam current is ≈2-nA, there are about 109 gamma ray emissions 
per second, and 106-s−1 events are registered in a ø2″ × 2″ LaBr3 
scintillator at 30-cm distance (29). This large gamma ray rate, as 
well as the inherent neutron background, poses a serious challenge 
on the detector and electronics design. Note that the so-called 
neutron background is mostly indirect, due to the detection of 
gamma rays following neutron interactions or neutron captures 
in surrounding materials, rather than from the interactions of 
neutrons in the detector itself.
In the field of nuclear medicine, commercial gamma cam-
eras are used in clinical routine to obtain images of gamma 
ray distributions. Hence, one may think that the imaging of 
prompt gamma rays is not an issue, as the technology is already 
established. However, together with the detection rate and 
background, the high gamma ray energies and polychromatic 
energy spectrum prevent the direct use of the gamma camera as 
PGI device. In comparison, the gamma ray energies in nuclear 
medicine range between 80 and 511-keV. This significant differ-
ence is outlined in Figure 3: larger collimators and detectors are 
needed to absorb high-energy prompt gamma rays, normally 
after multiple interaction processes. For example, a 2-mm layer 
of lead has a 99% attenuation power for 140-keV photons, but 
only 9% for 4.4-MeV gammas; a 1-cm thick CsI crystal has a 
detection efficiency of 98% for the first and just 15% for the latter. 
FiGURe 5 | illustrative sketch of the PGT method. The therapeutic 
proton p (the projectile) slows down as it penetrates the target and interacts 
with a nucleus, which emits a prompt gamma ray. The time between the 
entrance of the proton to the target (the start flag) and the arrival of the 
gamma ray to the detector (the stop flag at the yellow rectangle) encodes the 
proton transit time and gamma time of flight, which can be correlated to the 
depth of interaction of the proton (gamma emission point).
FiGURe 4 | incoherent scattering event in a two-plane Compton 
camera. The cone surface contains the possible incidence directions (any 
generatrix) of the initial photon (γ). It interacts with the scatterer plane and 
deposits an energy Ls. The scattered photon (γ′) releases the rest of the 
energy La in the absorber. The line connecting both interaction points (in 
orange) is the propagation direction of γ′. This defines the axis (directrix) of 
the aforementioned cone, with half-opening (scattering) angle θ and vertex at 
the scatter point.
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Thick collimators reduce the system efficiency and deteriorate 
the image quality, whereas large detectors increase critically 
the system price and enlarge the footprint. Hence, alternative 
concepts are needed.
Dedicated PGI detector systems have been designed and 
tested in the last decade based on active or passive collimation. A 
pin-hole camera (30) is the pioneer approach to scan the prompt 
gamma emission distribution in a right angle to the beam track. 
Many research groups have performed experiments based on 
slit cameras at proton or carbon beams (31–37). The knife-edge-
shaped camera has demonstrated the feasibility of millimeter 
range verification at clinical current intensities (38) in real time 
on a spot basis with realistic treatment plans and heterogeneous 
phantoms (39).
Among actively collimated systems, most efforts are con-
centrated on the Compton camera (40). It comprises multiple 
position sensitive gamma ray detectors, which are arranged in 
one scatterer and one absorber, or in several scatter planes. The 
prompt gamma rays reach the detectors, and the energy deposit 
as well as the point of interaction in each plane are measured, 
cf. Figure  4 for the two-plane camera. The Compton equation 
(41) relates the scattering angle θ to the initial (Eγ) and final (Eγʹ) 
photon energies:
 
E L L
E L
E E
γ
γ
γ
= +
=
= − / − /




s a
a
ecos m c
′
′ γθ 1 1 1
2
 (1)
where Ls and La are the energies released in scatterer and 
absorber, respectively, and mec2 = 511-keV is the electron rest 
energy. In contrast to a slit camera, no collimation is needed 
in order to reconstruct the angle of incidence of the gamma 
ray, and two-dimensional (2D) or even three-dimensional 
(3D) images instead of one-dimensional (1D) profiles may 
be obtained. More single gamma rays and directions can be 
detected, but the condition of simultaneous interaction in the 
different camera stages limits the overall efficiency. Furthermore, 
the instrumentation requirements in terms of spatial, time, and 
energy resolution for the detectors of a Compton camera are 
especially high, and the reconstruction algorithm is complex 
and computationally intensive, as the incident direction can-
not be recovered univocally for each event. Nowadays, a PGI 
Compton camera prototype demonstrating range verification 
in a clinical scenario is still a challenge several institutes aim at 
(42–47), and the only published experimental results at a proton 
beam are constrained to <2-MeV gammas (48, 49) or to beam 
currents far below the clinical case (50). Technical complexity, 
electronics expense, low coincident efficiency, high detector 
load, radiation background, and the elevated percentage of 
random coincidences are intrinsic hurdles that cast doubts on 
the applicability of this concept (19).
In the recent years, one can identify a trend toward less 
complicated PGI systems, at least concerning hardware. These 
may have a faster translation into clinical practice due to their 
lower price (35, 37, 51). The Prompt Gamma Ray Timing (PGT) 
method (28) is one of these novel approaches, which relies on a 
single monolithic detector with excellent timing resolution and 
no collimation. As a consequence of the measurable transit time 
of ions through matter, the detection times of prompt gamma 
rays encode essential information about their spatial emission 
point. Figure  5 illustrates this physical effect: the deeper the 
proton interaction (prompt gamma emission) point, the larger 
the proton transit time and time of flight of the gammas to the 
detector. Applying the Continuous Slowing Down Approximation 
(CSDA), the transit time can be derived mathematically (28) if the 
FiGURe 6 | Sketch of the LSO2 (left) and BGO1 (right) block detectors with the PMT numbering convention and crystal coordinate system, namely, 
the XBlock and YBlock axis (relative position between 0 and 1). Crystals are depicted in orange, PMTs in blue, and the light guide in yellow. Reproduced with 
permission from Ref. (53).
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initial beam energy E0 and target composition are known. First, 
the proton energy variation per unit length yields
 
d
d
E
z
z S E= −ρ( ) ( ) (2)
where E is the kinetic energy, ρ (z) the mass density of the target 
at a depth z, and S(E) the stopping power, that depends on target 
material and thus indirectly on the depth z. The kinetic energy E 
of the proton at any depth z > z0 is
 
E z E z S E z z
z
z
( ) ( ) ( ( ))= − ′ ′∫0
0
ρ ′ d  (3)
The relativistic velocity v of the particle is a function of the 
kinetic energy E:
 
v E E m( ) ( )= − + / −c 1 1 2 2pc  
(4)
where mp is the proton rest mass. Finally, the equation of the 
proton transit time yields
 
t z
v E
z
v E z E S E
E
z
z
E z
E
p d d( ) ( ) ( ) ( ( )) ( )( )
= ′ =
′∫ ∫0
01 1
ρ  
(5)
where dz′ has been exchanged with dE using equation (2).
The low cost and small footprint of PGT makes this concept 
very tempting. A major limitation is that the time spectra are 
not only blurred by the resolution of the detector but also by the 
time width of the accelerated bunches. This implies that the PGT 
method is not applicable at all clinical accelerators: only to those 
with a specific micro-time structure. For the widespread accelera-
tor C230 (5), the micro bunch time spread can reach up to 2-ns 
for clinical beam energies (29). Here, range shifts can be identified 
based on distribution momenta. It is under exploration whether 
PGT is only applicable for pencil beams or also for passively scat-
tered ones. In order to know if other types of clinical accelerators 
are compatible with the PGT approach, the specific micro pulse 
structure has to be measured.
Rather than an in-depth review of the literature, this manu-
script provides a summary of two separate topics developed 
within the collaborative framework of ENTERVISION (52): the 
characterization of detector components for the absorber plane of 
a clinical Compton camera and the first test of the PGT method 
with heterogeneous phantoms at a clinical proton center, cor-
responding to the publications (53) and (29), respectively.
2. COMPARiSON OF BGO AND LSO 
SCiNTiLLATiON DeTeCTORS
Bi4Ge3O12 (BGO) and Lu2SiO5:Ce (LSO) scintillators are straight-
forward candidates to absorber detectors of a Compton camera 
aiming at PGI. These are used traditionally in Positron Emission 
Tomography (PET) scanners. Despite its higher price and 30% 
lower photoabsorption efficiency, LSO has gained importance 
due to its higher light yield and fast decay time. It is questionable 
if this conclusion can be transcribed to the PGI scenario. In order 
to assess the choice between the two options, benchmark experi-
ments are conducted at different accelerators for comparing BGO 
and LSO detectors in terms of energy, spatial, and time resolution. 
Other factors, such as intrinsic radiation, absorption efficiency, 
and cost-effectiveness ratio, are also discussed.
2.1. Materials
The basic detection unit in commercial PET scanners is the block 
detector. It consists of a square matrix of segmented or pixellated 
scintillating crystals coupled to four light-sharing Photomultiplier 
Tubes (PMT), as depicted in Figure 6. The pixel where the gamma 
FiGURe 7 | Relative energy resolution Re = Σe/E of the LSO2 (black 
line) and BGO1 (red line) block detectors as a function of energy 
deposit E. ΣE refers to the FWHM of the photopeak. The empirical fit to the 
experimental points is R EE MeV= . ± . / / + . ± .( ) ( )3 8 0 3 5 6 0 3% % for LSO2 
and R EE MeV= . ± . / / + . ± .( ) ( )9 2 0 5 3 7 0 4% %  for BGO1. Reproduced with 
permission from Ref. (53).
TABLe 1 | Comparison of the properties of the different block detectors 
from Siemens Medical Solutions USA, inc. Molecular imaging Division, 
whose sketch is depicted in Figure 6.
Detector name LSO2 BGO1
Active volume (mm3) 52.7 × 52.7 × 20.0 52.7 × 52.7 × 20.0
Granularity Independent pixels Segmented crystal
Pixel matrix 13 × 13 8 × 8
Pixel dimensions (mm3) 4.0 × 4.0 × 20.0 6.4 × 6.4 × 20.0
Light guide Coupled to block Cut into block
Operating voltage +900 V +1350 V
Commercial scanner Biograph PET/CT ECAT EXACT 47 PET
Spatial dimensions are given as height × width × depth. Reproduced with permission 
from Ref. (53).
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ray interacts can be calculated based on the ratio of light collected 
by each PMT. The block detectors used in this comparative study 
and their properties are listed in Table 1. They are named as LSO2 
and BGO1 when referring to the concrete detector results, in 
contrast to LSO and BGO when speaking about general features 
of the scintillation materials.
2.2. Results
In Figure  7, the relative energy resolution RE as Full Width at 
Half Maximum (FWHM) of the LSO2 and BGO1 detectors is 
compared. The energy resolution of LSO2 is better across the 
whole energy range. At 511-keV, RE,LSO2 ≈ 11% and RE,BGO1 ≈ 18%. 
Nonetheless, the differences are less pronounced for high-energy 
photopeaks (53, 54). At 4.4-MeV, RE,LSO2 ≈ 7% versus RE,BGO1 ≈ 8%. 
In other words, LSO2 excels at the PET scenario (below 1-MeV), 
whereas for the PGI scenario (above 2-MeV), the difference in 
performance is less significant, and the higher price of LSO does 
not imply a much better detector quality.
The reason for the comparable energy resolution at high 
energies is the following. The relative energy resolution RE 
depends on two independent contributions: the statistical and 
the intrinsic one. The first one depends on the light yield and is 
proportional to the inverse square root of number of (collected) 
scintillation photons. The latter is due to non-linearity effects 
(55) and is dependent on the crystal structure. At low photon 
energies, i.e., the range of usual radioactive sources or in case 
of PET, the statistical contribution dominates over the intrinsic 
one. As LSO has a four times higher light yield than BGO, its 
energy resolution is significantly better. At high photon energies, 
i.e., the PGI energy range, the number of scintillation photons 
is larger, so that the statistical contribution is smaller and the 
intrinsic contribution starts to dominate. This intrinsic factor is 
comparable for BGO and LSO (54, 56, 57), which explains their 
similar performance concerning energy resolution at the PGI 
energy range.
With respect to the spatial resolution, one can conclude 
that the discrimination power between pixels of the flood map 
increases with the energy range for both block detectors, cf. 
Figure 8. This effect is also due to the lower statistical relative 
uncertainty of events with high-energy deposit. The spots in the 
flood map of BGO1 are broader than those of LSO2 in any case, 
but become very sharp in the PGI range. This points out that one 
could segment the BGO1 block detector in, e.g., 13 × 13 instead 
of 8 ×  8 and achieve the spatial resolution of LSO2 without 
jeopardizing the pixel discrimination in the flood map of the 
PGI range.
Regarding the time resolution, cf. Figure 9, the LSO2 detector 
beats BGO1 over the whole energy range thanks to the larger light 
yield and shorter decay time. A good time resolution is mandatory 
for a PGI Compton camera in order to suppress delayed radiation 
background (58). In order to analyze if the timing resolution of 
BGO1 is sufficient for this goal, we calculate the figure of merit 
FoMBSR (59):
 
FoM
TBSR
t det t bunch
bunch
= −
+, ,1
2 2Σ Σ
 
(6)
where Σt,det is the detector time resolution as FWHM, Σt,bunch the 
bunch time spread (FWHM), and T fbunch bunch=
−1  the bunch period 
(the inverse of the radio frequency). This ratio measures the 
amount of background that can be suppressed thanks to timing 
measurements in a pulsed accelerator. In the case of the C230 
machine, where Tbunch = 9.4-ns and Σt,bunch ≈ 2-ns (for 100-MeV 
protons) (29), the background suppression ratios for 4-MeV 
prompt gammas are FoMBSR,LSO2 = 84% and FoMBSR,BGO1 = 64%. 
LSO2 has undoubtedly better performance, but BGO1 could be 
also acceptable.
Other material features, such as the decay time and the intrin-
sic radioactivity, are worth to discuss. The decay time of BGO 
(7.5 times longer than LSO) implies a limit of around 300-kcps 
detector load. Taking into account the high rates expected in 
the PGI scenario, about 1-Mcps, one might be forced to reduce 
the area of the BGO block detectors or increase the distance 
to the beam axis. These rates are also quite challenging for the 
electronics and data processing. On the other hand, it is well 
known that LSO has a high intrinsic radioactivity below 1-MeV 
FiGURe 8 | Block detector flood map (top figure: LSO2 and bottom figure: BGO1) for different energy ranges at the eLBe accelerator (distortion 
correction applied for LSO2). Non-uniformities are due to the fact that the focused bremsstrahlung beam spot is smaller than the detector size as well as the 
different extension (number of bins) of each pixel spot in the map. Reproduced with permission from Ref. (53).
FiGURe 9 | Time resolution Σt,det (FwHM) of the LSO2 (black line) and 
BGO1 (red line) block detectors measured at the eLBe accelerator as a 
function of the released energy. The experimental points are approximately 
reproduced by the curves Σt det ps MeV ps, = ± / / + ±( ) ( )460 10 80 5E  for 
LSO2 and Σt det ps MeV ps, = ± / / + ±( ) ( )4900 500 10 10E  for BGO1. 
Reproduced with permission from Ref. (53).
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due to 176Lu, namely, through β− decay and subsequent gamma 
ray cascade. The simultaneous detection of the electron (stopped 
in the LSO crystal) and the gamma ray (in the scatterer plane) 
could produce a significant fraction of false coincidences in a 
Compton camera.
3. PROMPT GAMMA RAY TiMiNG wiTH 
HeTeROGeNeOUS TARGeTS
The PGT method is a promising and novel method for range 
verification proposed by Golnik et al. (28) based on experiments 
with homogeneous phantoms at a research accelerator. To fur-
ther explore its potential and the limitations that may appear 
when translating the concept to a realistic irradiation scenario, 
specific experiments at a clinical proton center with heteroge-
neous targets are conducted. The concrete goals are to test the 
robustness of the PGT method, its precision, and limitations, as 
well as the capability of detecting range shifts due to heterogenei-
ties. Furthermore, the next steps toward a clinical PGT prototype 
are identified.
3.1. Materials
The experiment is carried out at the Westdeutsches 
Protonentherapiezentrum Essen (WPE), Germany. This clinical 
proton center comprises a C230 cyclotron, with a radio frequency 
close to 106-MHz. A horizontal pencil beam (no scanning) in 
the gantry treatment room irradiates a cylindrical target, see 
Figure  10 (bottom). The inner shell contains slices of custom 
thickness and composition, so that different heterogeneous 
targets can be configured. Available materials are polymethyl 
methacrylate (PMMA), air (hollow slice), and cortical bone. The 
detectors listed in Table 2 are set up at an angle α and distance 
d, as described in Figure  10 (top). Whenever a target is thick 
TABLe 2 | Monolithic scintillation detectors available in the experiment.
Alias Material ø × Length Rationale
B1 BaF2 [25:38] mm × 30 mm Time resolution
B3 BaF2 48 mm × 31 mm Time resolution
L0 LaBr3:Ce 2″ × 2″ Energy resolution
B3 and L0 are cylindrical, whereas B1 is a tapered cone (for optimum time resolution). 
Reproduced with permission from Ref. (29).
FiGURe 10 | Top: sketch of the experimental setup at the wPe proton therapy facility and of the longitudinal cross section of the target. The 
accelerated protons bunched with 106 MHz collide with the PMMA cylindrical target. It contains a cavity or bone insert of thickness h located at a distance f from 
the beam entrance point. Bottom: photograph of the experimental setup with three detectors at different ring angles α. The linear stage on the center of the ring 
holds the two hollow joined half cylinders, in which PMMA, cavity, or bone slices can be inserted. The beam incidence is horizontal from the left, where the snout of 
the nozzle is seen. Reproduced with permission from Ref. (29).
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enough to completely stop the impinging protons, we label it as 
full (for a given proton energy).
3.2. Results
The bunch time spread is an important limiting factor for the 
PGT method. In Figure 11 (left), the bunch width is characterized 
as a function of the proton energy, ranging from 350-ps at 230-
MeV to 2-ns at 100-MeV. The time spread can be reduced up to 
a factor of two by adjusting the momentum spread limiting slits, 
cf. Figure 11 (right), the main component of the energy selection 
system of the C230 cyclotron (60).
For the acquisition of PGT spectra, the detection time of the 
gamma rays with respect to the arrival of the protons to the target 
has to be measured. As usual in research accelerators, the radio 
frequency can be used as reference time for the bunch arrival 
(except for an offset). However, Figure 12 shows that this offset is 
not constant on a large time scale (29). These phase drifts of the 
proton bunch with respect to the RF signal may be caused due 
to temperature changes or main coil current instabilities, among 
other factors.
With regard to homogeneous targets, the stacked target experi-
ment is accomplished as follows: homogeneous PMMA targets 
of various thicknesses are irradiated with 230-MeV protons. The 
increase of the target thickness correlates to an increase of the 
area of the PGT distribution and a shift to the right in its mean 
value, due to the enlarged region of prompt gamma emission, 
as observed in Figure 13 (left). As the bunch time spread is sig-
nificantly lower than the proton transit time, one can resolve the 
prompt gamma emission density as a function of the (timewise) 
depth with much less blurring than for 160 or 100-MeV proton 
energies. In Figure 13 (right), we calculate the PGT distributions 
according to the analytical simple Box (simBox) model (28). 
The shape is qualitatively similar to the experimental spectra, 
but the model is too simple to reproduce, e.g., the fall-off edge 
corresponding to the Bragg peak or the background radiation.
FiGURe 11 | Left: PGT spectra of the B1 detector with a thin PMMA target for three different proton energies and the usual slit closing (25-mm) at the 
wPe gantry. Right: bunch time spread Σt,bunch at 100-MeV proton energy and a full PMMA target for the B3 detector. Reproduced with permission from Ref. (29).
FiGURe 12 | Left: PGT spectra of the B3 detector, a homogeneous PMMA target and a proton energy of 230-Mev. Independent redundant 
measurements of about 5-min with a separation of around 1-h are overlaid. Right: PGT spectra of the B3 detector, a full homogeneous PMMA target, and a proton 
energy of 160-MeV for different values of the main coil current of the cyclotron (detailed in the legend). Reproduced with permission from Ref. (29).
9
Hueso-González et al. Prompt Gamma Ray Timing
Frontiers in Oncology | www.frontiersin.org April 2016 | Volume 6 | Article 80
FiGURe 13 | Left: experimental PGT spectra of the B1 detector for 230-Mev protons and different PMMA target thicknesses. Right: spectra calculated with the 
analytical simBox model (28). Both: the two vertical dashed lines refer to the expected front face and proton range positions. Reproduced with permission from Ref. (29).
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FiGURe 15 | Left: experimental PGT spectra of the L0 detector for 230-Mev protons and a bone insert inside the full (400-mm) PMMA target at f and 
h (front face position and thickness as described in Figure 10). Right: time to distance axis conversion from the left PGT spectra after application of stopping 
power, sensitivity, and gamma time-of-flight corrections as well as background subtraction. z refers to the depth with respect to the target’s front face (beam 
entrance point). Vertical dashed lines mark the centroid of the bump according to the simBox model. Reproduced with permission from Ref. (29).
FiGURe 14 | experimental PGT spectra of the L0 detector for 230-Mev protons and different air cavities inside the full (400-mm) PMMA target at f 
and h (front face position and thickness as described in Figure 10). Reproduced with permission from Ref. (29).
Concerning heterogeneous targets, air cavities of different 
thicknesses are placed at different depths inside a full PMMA 
target. The experimental results are shown in Figure  14. The 
deficit in the gamma ray production inside the air cavity can be 
identified as a dip in the PGT spectra at a time position and with 
a magnitude correlated to its location and thickness, respectively. 
The falling edge of the spectrum shifts steadily to the right accord-
ing to the cavity thickness (beam overshoot).
An analogous experiment with a bone insert (20-mm thick) 
at different positions is carried out (29). The resulting PGT spec-
tra are depicted in Figure 15 (left). An increase of the gamma 
ray production due to the higher density of bone is visible in 
the PGT spectrum at a time correlated to the insert position. 
A shift to the left in the falling edge of the distribution can be 
identified (undershoot) with respect to the homogeneous case. 
In Figure  15 (right), the PGT spectra are converted to depth 
profiles by using the transit time equation, cf. equation  (5), 
and applying detector solid angle and gamma time-of-flight 
corrections.
In Figure 16, for 230-MeV protons, the effect of a beam over-
shoot (air cavity) and undershoot (bone insert) on PGT spectra is 
compared with respect to a reference measurement (homogene-
ous PMMA target). Moreover, the detectability of the range shift 
based on the location of the trailing edge is analyzed as a function 
of the number of irradiated protons. For clinical treatment plans, 
the strongest spot in pencil beam scanning, which is usually at 
the distal edge, yields close to 108 protons. This hints that a single 
detector is able to recover 5-mm range errors of the distal spot 
based on the PGT method with realistic beam currents at the 
C230 accelerator.
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FiGURe 16 | Top row and bottom left plot: PGT spectra of the L0 detector for 230-Mev protons. The homogeneous case (red curve) corresponds to a full 
PMMA target (400-mm). A heterogeneous slice is placed inside the full PMMA target at f = 169-mm and h = 5-mm (air cavity – blue curve) or f = 169-mm and 
h = 20-mm (bone insert – black curve), where f and h are the front face position and thickness, as described in Figure 10. The legend header contains the number 
of protons associated with each spectrum. Bottom right: shift of the falling edge with respect to the homogeneous case depending on the number of protons. The 
dashed lines depict the expected shift of the trailing edge according to the simBox model. Reproduced with permission from Ref. (29).
4. DiSCUSSiON
Prompt gamma rays, produced in nuclear reactions of accelerated 
protons with tissue, are valid signatures for retrieving the range of 
therapeutic protons. Several imaging systems are under develop-
ment in the scientific community. Among others, the Compton 
camera and the Prompt Gamma Ray Timing (PGT) method have 
been studied intensively during the last years in collaboration 
with the ENTERVISION project (52).
A Compton camera requires position-sensitive detectors with 
high resolution and efficiency. The characterization of different 
candidate detectors in the PGI energy range is mandatory for 
assessing the material choice based on measurements that com-
plement previous simulations and textbook knowledge. BGO and 
LSO block detectors from commercial PET scanners are compared 
in terms of energy, spatial, and time resolution, as well as price, 
absorption efficiency, and intrinsic background. As expected, the 
overall performance of LSO is better, but BGO closes the gap in 
the PGI range. The reason is that the high gamma ray energies 
(compared to the PET scenario) and thus number of scintillation 
photons balances the lower light yield. In addition, BGO has a 
higher photoabsorption efficiency, no intrinsic radioactivity, and 
low cost. Hence, BGO is a competitive alternative for the absorber 
of a Compton camera, thanks to the superior cost-effectiveness 
ratio in the PGI field (53).
PGT is an innovative method for range assessment based on a 
low footprint detector setup at minimum expense. First tests at a 
clinical accelerator and with heterogeneous phantoms reveal the 
capability of measuring 5-mm range shifts (due to heterogenei-
ties) for beam spots with 108 protons (29). The bunch time spread 
is a crucial factor that affects the resolution of the PGT method. 
It depends on the delivered proton energy and the settings of the 
energy selection system. Furthermore, bunch phase drifts are 
found throughout the experiment, which pose a challenge on the 
robustness of the PGT method on a large time scale. Hence, it 
is advisable to introduce a proton bunch monitor (60, 61) that 
measures the bunch time structure as well as the potential phase 
drifts. A larger detector load and acquisition throughput are 
mandatory to improve the number of gamma rays detected per 
proton, so that statistically significant conclusions on range errors 
can be drawn for more spots of the treatment plan. Quantification 
of the range shifts based on more sophisticated models or simula-
tions are also necessary. Experiments with upgraded detectors 
and electronics, realistic treatment plans, and anthropomorphic 
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